NEW YORK (360Dx) – Quest Diagnostics announced today that is has completed its previously announced acquisition of Cleveland HeartLab, which will now become Quest's National Cardiometabolic Center of Excellence.
The 25,000 square-foot clinical lab will combine the expertise of Cleveland HeartLab's personalized evaluation of heart-disease risk, based on inflammation and other biomarkers, with Quest Cardio IQ lipid particle analysis and genetic metabolic testing. The center will study how new inflammation, genetic, and other biomarkers may help physicians identify at-risk patients that may not have been identified through cholesterol panels. The center will also look at how inflammation and genetic testing can help guide treatment protocols and improve outcomes.
In connection with the acquisition, Quest and Cleveland Clinic have finalized a strategic collaboration intended to speed commercialization of emerging innovations at Cleveland Clinic and its Lerner Research Institute. Quest and Cleveland Clinic also plan to collaborate on trials to demonstrate the clinical and economic value of these and other biomarkers.
Cleveland Clinic was one of the equity investors from whom Quest acquired Cleveland HeartLab. The plans for the acquisition and strategic relationship with Cleveland Clinic were first announced in October.
"Joining together with Cleveland HeartLab will expand access to cardiometabolic diagnostic innovations that can help patients identify their personal risk and achieve the best possible health outcomes. It supports our strategy to accelerate growth while also helping more patients gain the insight they need to lead healthier lives," Steve Rusckowski, chairman, president and CEO of Quest, said in a statement.